Medscape

Catumaxomab Effective in Treating Malignant Ascites

August 31, 2010 (Shenzhen, China) — Catumaxomab (Removab, Fresenius Biotech) is the first causal therapy against malignant ascites that has the approval of the European Commission. A phase 1/2 trial ...
ascopubs.org

Catumaxomab observational study to investigate efficacy and safety profile in clinical practice.

Phase II clinical trial to evaluate the safety of repeated cycles of intraperitoneal catumaxomab for the treatment of malignant ascites (SECIMAS). Background: The trifunctional anti-EpCAM/anti-CD3 ...
PharmiWeb

Pharmanovia Announces Launch of Korjuny (Catumaxomab) in Germany, a First-in-class Treatment for Malignant Ascites

Catumaxomab Is the Only Approved Drug Therapy for Malignant Ascites, a Rare and Debilitating Complication of Advanced-stage Cancer Launch Offers Prolonged Puncture-free Survival and Delayed ...
Nature

Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study

This is the first study investigating the safety and efficacy of the trifunctional antibody catumaxomab administered i.p. at the end of cytoreductive surgery and postoperatively prior to standard ...
The Globe and Mail

LINDIS BIOTECH AND PHARMANOVIA ANNOUNCE EUROPEAN MARKETING AUTHORISATION APPROVAL FOR CATUMAXOMAB, A FIRST-IN-CLASS TREATMENT FOR MALIGNANT ASCITES

CATUMAXOMAB BECOMES THE ONLY APPROVED DRUG THERAPY FOR MALIGNANT ASCITES, A RARE AND DEBILITATING COMPLICATION OF ADVANCED-STAGE CANCER UNDER A LICENSING AGREEMENT, LINDIS HAS GRANTED PHARMANOVIA THE ...
Financial Post

Pharmanovia Signs Novel Biologic In-Licensing Agreement With Lindis Biotech to Commercialise Catumaxomab for Treatment of Rare Condition, Malignant Ascites

Catumaxomab Received a Positive Opinion From the EMA’s Committee for Medicinal Products for Human Use (CHMP) at Its October 2024 Meeting and If Approved Catumaxomab Will Be the Only Approved Drug ...